Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Allergan plc    AGN   IE00BY9D5467

ALLERGAN PLC (AGN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Summary
  • In view of fundamental criteria, the company is among low performers as far as mid or long-term investment strategy is concerned.
  • For a short-term investment strategy, the company has poor fundamentals.
Strengths
  • Graphically speaking, the timing seems perfect for purchasing the stock close to the USD 158.72 support.
  • Historically, the company has been releasing figures that are above expectations.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
  • According to Thomson-Reuters' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
  • The company has insufficient levels of profitability.
  • One of the major weak points of the company is its financial situation.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • The technical configuration over the long term remains negative on the weekly chart below the resistance level at 204.65 USD
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
ALLERGAN PLC-2.56%53 014
JOHNSON & JOHNSON-7.02%349 006
NOVARTIS-2.94%224 221
PFIZER-1.33%213 155
ROCHE HOLDING LTD.-9.41%207 327
MERCK AND COMPANY-3.02%148 618
AMGEN4.92%132 428
BRISTOL-MYERS SQUIBB COMPAN..7.60%108 890
ABBOTT LABORATORIES3.36%102 678
NOVO NORDISK A/S-4.17%101 783
SANOFI-9.46%100 822
BAYER-5.85%100 123
GLAXOSMITHKLINE-2.00%91 577
ELI LILLY AND COMPANY-8.61%85 390
ASTRAZENECA-7.21%85 057
CELGENE CORPORATION-10.14%70 622
More Results
Financials ($)
Sales 2018 15 196 M
EBIT 2018 7 274 M
Net income 2018 -1 246 M
Debt 2018 22 990 M
Yield 2018 1,83%
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 5,00x
EV / Sales 2019 4,66x
Capitalization 53 014 M
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio -
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes
Chart ALLERGAN PLC
Duration : Period : Day
Allergan plc Technical Analysis Chart | AGN | IE00BY9D5467 | 4-Traders
Duration : Period : Week
Allergan plc Technical Analysis Chart | AGN | IE00BY9D5467 | 4-Traders